JPY 214.0
(0.47%)
Year | Revenue | Revenue Growth |
---|---|---|
2023 | 1 Million USD | 0.0% |
2022 | - USD | -100.0% |
2021 | 4.03 Million USD | 0.0% |
2020 | - USD | 0.0% |
2019 | - USD | 0.0% |
Year | Revenue | Revenue Growth |
---|---|---|
2024 Q1 | - USD | 0.0% |
2024 Q2 | - USD | 0.0% |
2023 Q4 | - USD | -100.0% |
2023 FY | 1 Million USD | 0.0% |
2023 Q3 | 1 Million USD | 0.0% |
2023 Q2 | - USD | 0.0% |
2023 Q1 | - USD | 0.0% |
2022 FY | - USD | -100.0% |
2022 Q4 | - USD | 0.0% |
2021 FY | 4.03 Million USD | 0.0% |
2020 FY | - USD | 0.0% |
Name | Revenue | Revenue Difference |
---|---|---|
KOHJIN BIO CO LTD | 4.77 Billion JPY | 99.979% |
PRISM BioLab Co.,LTD | 112.92 Million JPY | 99.114% |
GNI Group Ltd. | 26.01 Billion JPY | 99.996% |
Linical Co., Ltd. | 12.3 Billion JPY | 99.992% |
Trans Genic Inc. | 13.08 Billion JPY | 99.992% |
MEDINET Co., Ltd. | 661.54 Million JPY | 99.849% |
Soiken Holdings Inc. | 5.15 Billion JPY | 99.981% |
Cytori Cell Research Institute, Inc. | 1.56 Billion JPY | 99.936% |
AnGes, Inc. | 152.98 Million JPY | 99.346% |
OncoTherapy Science, Inc. | 610.11 Million JPY | 99.836% |
Nxera Pharma Co., Ltd. | 12.76 Billion JPY | 99.992% |
Immuno-Biological Laboratories Co., Ltd. | 816.7 Million JPY | 99.878% |
NanoCarrier Co., Ltd. | 135.5 Million JPY | 99.262% |
Carna Biosciences, Inc. | 1.62 Billion JPY | 99.938% |
CanBas Co., Ltd. | - JPY | -Infinity% |
D. Western Therapeutics Institute, Inc. | 428.36 Million JPY | 99.767% |
RaQualia Pharma Inc. | 1.9 Billion JPY | 99.947% |
Chiome Bioscience Inc. | 682.46 Million JPY | 99.853% |
Kidswell Bio Corporation | 2.43 Billion JPY | 99.959% |
PeptiDream Inc. | 28.71 Billion JPY | 99.997% |
Oncolys BioPharma Inc. | 63.03 Million JPY | 98.414% |
Ribomic Inc. | - JPY | -Infinity% |
SanBio Company Limited | - JPY | -Infinity% |
Healios K.K. | 121 Million JPY | 99.174% |
BrightPath Biotherapeutics Co., Ltd. | 72 Thousand JPY | -1288.889% |
Kubota Pharmaceutical Holdings Co., Ltd. | 39.88 Million JPY | 97.493% |
Delta-Fly Pharma, Inc. | - JPY | -Infinity% |
StemRIM | - JPY | -Infinity% |
CellSource Co., Ltd. | 4.51 Billion JPY | 99.978% |
FunPep Company Limited | 530 Thousand JPY | -88.679% |
Kringle Pharma, Inc. | 69.25 Million JPY | 98.556% |
Stella Pharma Corporation | 269.49 Million JPY | 99.629% |
TMS Co., Ltd. | - JPY | -Infinity% |
Noile-Immune Biotech Inc. | 316.81 Million JPY | 99.684% |
Cuorips Inc. | 23.1 Million JPY | 95.671% |
K Pharma,Inc. | 1 Billion JPY | 99.9% |
Takara Bio Inc. | 43.5 Billion JPY | 99.998% |
ReproCELL Incorporated | 2.42 Billion JPY | 99.959% |
PhoenixBio Co., Ltd. | 1.71 Billion JPY | 99.942% |
StemCell Institute Inc. | 2.48 Billion JPY | 99.96% |
Japan Tissue Engineering Co., Ltd. | 2.51 Billion JPY | 99.96% |
CellSeed Inc. | 190.13 Million JPY | 99.474% |